For Ph-negative relapsed or refractory (R/R) B-cell precursor acute lymphoblastic leukemia (ALL)
HARNESS THE POWER OF A
SINGLE-AGENT IMMUNOTHERAPY
Complete Remission or Complete Remission With
Partial Hematological Recovery Are Within Reach
41.6%
of evaluable patients achieved complete remission (CR) or
complete remission with partial hematological recovery (CRh*)
during the first 2 treatment cycles (n=77/185; 95% CI: 34.4-49.1)1
CR = complete remission, defined as ≤ 5% of blasts in the bone marrow, no evidence of disease, and full recovery of peripheral blood counts
(platelets > 100,000/microliter and absolute neutrophil counts [ANC] > 1,000/microliter).1
CRh* = complete remission with partial hematological recovery, defined as ≤ 5% of blasts in the bone marrow, no evidence of disease,
and partial recovery of peripheral blood counts (platelets > 50,000 /microliter and ANC > 500/microliter).1
INDICATION
BLINCYTO® is indicated for the treatment of Philadelphia chromosome-negative
relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
This indication is approved under accelerated approval. Continued approval
for this indication may be contingent upon verification of clinical
benefit in subsequent trials.
IMPORTANT SAFETY INFORMATION
WARNING: CYTOKINE RELEASE SYNDROME
and NEUROLOGICAL TOXICITIES
• Cytokine Release Syndrome (CRS), which may
be life-threatening or fatal, occurred in patients
receiving BLINCYTO®. Interrupt or discontinue
BLINCYTO® as recommended.
• Neurological toxicities, which may be severe,
life-threatening or fatal, occurred in patients
receiving BLINCYTO®. Interrupt or discontinue
BLINCYTO® as recommended.
TARGE T. ENGAGE. ACTIVATE.